Preparation and in vitro evaluation of slow release ketoprofen microcapsules formulated into tablets and capsules.

Ketoprofen powder was encapsulated with Eudragit RL/RS polymer solutions in isopropanol-acetone 1:1, using a simple and rapid method. Microcapsules were prepared using Eudragit solutions with different RL/RS ratios. The encapsulation process produces free-flowing microcapsules with good drug content and marked decrease in dissolution rate. The retardation in release profile of ketoprofen from microcapsules was a function of the polymer ratio employed in the encapsulation process. In vitro release of ketoprofen from microcapsules either filled in gelatin capsules or compressed into tablets, using calcium sulphate as diluent, confirmed the efficiency of the encapsulation process for preparing prolonged release medication. A capsule formulation with optimum sustained-release profile was suggested.     

盐酸二甲双胍缓释胶囊处方筛选及工艺研究

目的：研究盐酸二甲双胍缓释胶囊的处方筛选及工艺。方法：以释放度作为判断标准,对包衣材料的种类用量及工艺进行考察,进行处方筛选。结果：素丸以微晶纤维素为空白丸心,聚维酮为粘合剂,采用溶液法上药；包衣液以Eudragit RS100为主料,邻苯二甲酸二乙酯为增塑剂,乙醇为溶剂,利用流化床技术制备缓释胶囊。结论：通过这种方法制得的盐酸二甲双胍缓释胶囊具有较好的缓释效果,有继续开发的价值。     

Preparation and in vitro evaluation of slow release ketoprofen microcapsules formulated into tablets and capsules

Abstract

Ketoprofen powder was encapsulated with Eudragit RL/RS polymer solutions in isopropanol-acetone 1:1, using a simple and rapid method. Microcapsules were prepared using Eudragit solutions with different RL/RS ratios. The encapsulation process produces free-flowing microcapsules with good drug content and marked decrease in dissolution rate. The retardation in release profile of ketoprofen from microcapsules was a function of the polymer ratio employed in the encapsulation process. In vitro release of ketoprofen from microcapsules either filled in gelatin capsules or compressed into tablets, using calcium sulphate as diluent, confirmed the efficiency of the encapsulation process for preparing prolonged release medication. A capsule formulation with optimum sustained-release profile was suggested.     

Sealing liquid-filled pectinate capsules with a shellac coating

Liquid-filled pectinate capsules have a large potential for the controlled and site-specific delivery of liquid drugs. Earlier studies have shown that pure pectinate capsules can store drugs only for a few minutes. Here, we show that the retention time can be extended to several hours by coating the capsules with the natural resin shellac. A bilberry extract containing anthocyanins with promising therapeutic properties was used as model drug to characterize the permeability of the capsules by in vitro drug release measurements. Characterizing the structure of the double-layered capsule membranes by NMR microscopy, we optimized the capsule production by adjusting the pH-value in the coating process and the gelation time of the pectinate hydrogel layer. A comparison of the layer thicknesses with drug release measurements reveals that capsules with the thinnest shellac layers provide the best entrapment. Additional squeezing experiments show that the shellac layer makes the capsules also mechanically more stable.     

Sealing liquid-filled pectinate capsules with a shellac coating

Liquid-filled pectinate capsules have a large potential for the controlled and site-specific delivery of liquid drugs. Earlier studies have shown that pure pectinate capsules can store drugs only for a few minutes. Here, we show that the retention time can be extended to several hours by coating the capsules with the natural resin shellac. A bilberry extract containing anthocyanins with promising therapeutic properties was used as model drug to characterize the permeability of the capsules by in?vitro drug release measurements. Characterizing the structure of the double-layered capsule membranes by NMR microscopy, we optimized the capsule production by adjusting the pH-value in the coating process and the gelation time of the pectinate hydrogel layer. A comparison of the layer thicknesses with drug release measurements reveals that capsules with the thinnest shellac layers provide the best entrapment. Additional squeezing experiments show that the shellac layer makes the capsules also mechanically more stable.     

Evaluation of the sustained release properties of Eudragit RS, RL and S (acrylic resins) microcapsules containing ketoprofen in beagle dogs

Eudragit RS, RS-RL, RL and S microcapsules containing ketoprofen were prepared by the solvent evaporation process in oil phase. The sustained release effect of these microcapsules and Oruvail, the representative commercial product of ketoprofen, was evaluated by the pH shift dissolution method and in beagle dogs, respectively. The dissolution patterns of ketoprofen from Eudragit RS, RS-RL and RL microcapsules were independent of the pH of the dissolution medium, and its dissolution rate increased with increasing content of ketoprofen in microcapsules. But the dissolution pattern of ketoprofen from Eudragit S microcapsules and Oruvail was found to depend on the pH of the dissolution medium. The rank order of the dissolution rate of ketoprofen from Eudragit RS, RS-RL and RL microcapsules containing 30 and 40 per cent (w/w) ketoprofen was sufficiently clear as to enable prediction of the relative bioavailability of ketoprofen from these microcapsules. In vivo evaluation using beagle dogs, sustained release effects of Eudragit RL and Eudragit S microcapsules containing 30 per cent (w/w) ketoprofen and Eudragit RS-RL microcapsules containing 40 per cent (w/w) ketoprofen were almost the same as or slightly superior to that of Oruvail.     

Use of ion-exchange resins to prepare 100 microm-sized microcapsules with prolonged drug-release by the Wurster process

Ion-exchange resin (IER)--drug complexes were used as core materials to explore their capability to prepare a 100 microm-sized, highly drug-incorporated microcapsule with a prolonged drug release by the Wurster process. Diclofenac sodium was loaded into Dowex 1-X2 fractionated into 200--400 mesh and subsequently microencapsulated with two types of aqueous colloidal polymer dispersion, Aquacoator Eudragit RS30D. The mass median diameter and drug content of the microcapsules thus obtained were 98 microm and 46% with Aquacoat, and 95 microm and 50% with Eudragit RS30D, respectively. Each microcapsule was obtained at a product yield of 94%. The rate of drug release from the microcapsules was highly dependent on the encapsulating materials. For the microcapsules coated with Aquacoat, diclofenac sodium was found to be rapidly released over 4 h, even at a 25 wt% coating level because of cracks on the microcapsule surfaces resulting from the swelling stress of the drug-loaded IER cores. In contrast, significantly prolonged drug-release was achieved in the microcapsules prepared with Eudragit RS30D: even such a very low coating level as 3 wt% provided an exceptionally prolonged drug-release over 24 h. The results indicated that the use of IER along with a flexible coating material would be a feasible way to prepare a prolonged release type of microcapsules with a diameter of 100 microm and a drug content of more than 50% by the Wurster process.     

Studies on the development for sustained release preparation (II): Preparation and evaluation of eudragit microcapsules of sodium naproxen

The microencapsulation of sodium naproxen with Eudragit RS was studied by coacervation/phase separation process using Span 80 in mineral oil/acetone system. Various factors which affect the microencapsulation, e.g., stiming speed, and surfactant concentration, Eudragit RS concentration and loading drug amounts were examined. For the evaluation of the prepared microcapsules, release rate, particle size distribution and surface appearance as well asin vivo test were carried out. The addition of n-hexane and freezing of microcapsules accelerated the hardening of microcapsules. The optimum concentration of Span 80 to prepare the smallest microcapsules was the same value with the CMC of Span 80 in solvent system. When 1.5% (w/w) Span 80 was used, the smallest microcapsules were formed (30.02±5.05 μm in diameter) belonging to the powder category showing smooth, round and uniform surface. The release of sodium naproxen was retarded by microencapsulation with Eudragit RS. The Eudragit RS microcapsules showed significantly increased AUC and MRT and decreased Cl/F in rabbits.     

Theoretical and experimental investigations into the delamination tendencies of bilayer tablets

A controlled release resinate beads of betahistine diHCl (BHCl), a short half-life freely water soluble drug, was developed to allow once-daily administration to improve patient compliance and eliminate the risk of intolerance of the drug. BHCl-resin complex was subsequently coated with Eudragit RS100. A 2(4) full factorial design was employed for optimization and to explore the effect of Eudragit RS100 concentration in the coating solution (X(1)), the coating percentage (X(2)), the speed of rotation (X(3)) and the concentration of plasticizer (PEG 400) (X(4)) on the release rate of the drug from the microcapsules. The extent of coating (Y(1)), and the percentage drug released at given times (Y(2), Y(3) and Y(4)) were selected as dependent variables. The optimization process was performed for X(1), X(2), X(3) and X(4) using target ranges of these responses determined based on target release model deduced form zero-order dissolution profile of BHCl for once-daily administration. The levels of X(1), X(2), X(3) and X(4) of optimized BHCl microcapsules are 14.42%, 50.63%, 1495rpm and 9.94%, respectively. The calculated value of f(2) for the optimized BHCl microcapsules filled into hard gelatin capsules was 67.03 indicating that the dissolution profiles of the optimized formulation is comparable to that of the target release model. It could be concluded that a promising once-daily extended-release microcapsules of the highly water soluble drug, BHCl, was successfully designed.     

Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit) RS, ethylcellulose and shellac.

Drug-layered pellets were coated with micronized polymer powders (Eudragit) RS, ethylcellulose, and shellac) by a dry powder coating technique as an alternative to organic- and aqueous-based coatings (Eudragit) RS 30D, Aquacoat) ECD) were investigated. High plasticizer concentrations (40%) and a thermal after-treatment (curing) were necessary for the coalescence of the polymer particles and good film formation. Ethylcellulose required a higher curing temperature and time than Eudragit) RS because of its higher glass transition temperature (133 versus 58 degrees C). A smaller polymer particle size also promoted film formation. In general, pellets coated with polymer powders required higher coating levels to obtain similar drug release patterns as pellets coated with organic polymer solutions and aqueous polymer dispersions.     

Release of diltiazem from Eudragit microparticles prepared by spray-drying

Microparticles containing diltiazem hydrochloride were prepared by the spray-drying technique using acrylatemethacrylate copolymers, Eudragit RS and Eudragit RL, as coating materials. The choice of solvent used during spray-drying determined the structure of the resultant microparticles. Spray-drying using dichloromethane as the solvent resulted in microspheres where the drug was distributed in the coating polymer matrix, whereas using toluene gave microcapsules with the drug coated by the polymer. The particle size distribution for both microspheres and microcapsules was narrow, with mean particle size below 10 μm. DTA-analysis showed that the drug was amorphous in the microspheres but crystalline in the microcapsules. The release pattern of diltiazem hydrochloride was affected by microparticle structure, whether the structure was matrix (microspheres) or reservoir (microcapsules). The results indicate that spray-drying is a method that can be used to prepare microparticles from the Eudragit acrylic resins RL and RS with a narrow particle size distribution. It is concluded that drug release rate can be controlled by choice of polymer type and production conditions during spray-drying.     

药物树脂复合物的表面包衣法微囊化工艺

以马来酸氯苯那敏为模型药物,采用离子交换树脂(Amberlite IRP-69)为载体制备药物树脂复合物。再以丙烯酸树脂(Eudragit RS100)为包衣材料,通过离子交换的方式对氯苯那敏树脂复合物进行表面包衣,并对表面包衣工艺参数的影响进行单因素考察,以期制备具有良好缓释性能的氯苯那敏树脂复合物微囊。在本试验范围内,药物树脂复合物的载药量越高、Eudragit RS100浓度越高、反应介质(95%乙醇)用量越多以及反应温度越高,药物释放越慢。上述结果提示,表面包衣法制备药物树脂复合物缓释微囊的生产操作简单,工艺重现性好,可进一步作制剂加工。     

Correlation of surface characteristics with ease of production and in vitro release of sodium salicylate from various enteric coated microcapsules prepared by pan coating

Nonpareil seeds were loaded with sodium salicylate and enteric coated with organic solvent based systems including polyvinyl acetate phthalate, cellacephate (CAP), shellac, hydroxypropylmethylcellulose phthalate, or Eudragit L as film former. Details of the pan coating procedure used were described. The CAP product showed optimum surface continuity when examined by scanning electron microscopy. The shellac product exhibited least aggregation during coating and consequently gave highest yields. Dissolution studies on the microcapsules in simulated gastric and intestinal media indicated that the CAP coated microcapsules had the most satisfactory enteric properties.     

Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles

The objective of this study was to develop and evaluate a rupturable pulsatile drug delivery system based on soft gelatin capsules with or without a swelling layer and an external water-insoluble but -permeable polymer coating, which released the drug after a lag time (rupturing of the external polymer coating). The swelling of the gelatin capsule itself was insufficient to rupture the external polymer coating, an additional swelling layer was applied between the capsule and the polymer coating. Croscarmellose sodium (Ac-Di-Sol) was more effective as a swelling agent than low and high molecular weight hydroxypropylmethyl cellulose (HPMC; E5 or K100M). Brittle polymers, such as ethyl cellulose (EC) and cellulose acetate propionate (CAPr), led to a better rupturing and therefore more complete drug release than the flexible polymer coating, Eudragit RS. The lag time of the release system increased with higher polymer coating levels and decreased with the addition of a hydrophilic pore-former, HPMC E5 and also with an increasing amount of the intermediate swelling layer. The water uptake of the capsules was linear until rupture and was higher with CAPr than with EC. Soft gelatin capsule-based systems showed shorter lag times compared to hard gelatin capsules because of the higher hardness/filling state of the soft gelatin capsules. The swelling pressure was therefore more directed to the external polymer coating with the soft gelatin capsules. Typical pulsatile drug release profiles were obtained at lower polymer coating levels, while the release was slower and incomplete at the higher coating levels. CAPr-coated capsules resulted in a more complete release than EC-coated capsules.     

Correlation of surface characteristics with ease of production and in vitro release of sodium salicylate from various enteric coated microcapsules prepared by pan coating

Abstract

Nonpareil seeds were loaded with sodium salicylate and enteric coated with organic solvent based systems including polyvinyl acetate phthalate, cellacephate (CAP), shellac, hydroxypropylmethylcellulose phthalate, or Eudragit L as film former. Details of the pan coating procedure used were described. The CAP product showed optimum surface continuity when examined by scanning electron microscopy. The shellac product exhibited least aggregation during coating and consequently gave highest yields. Dissolution studies on the microcapsules in simulated gastric and intestinal media indicated that the CAP coated microcapsules had the most satisfactory enteric properties.     

Design of prolonged-release microcapsules containing diclofenac sodium for oral suspensions and their preparation by the Wurster process

Prolonged-release microcapsules of diclofenac sodium (DS), an acidic drug, applicable as an oral suspension for twice-a-day administration were designed. The microcapsules with a mass median diameter of around 100 μm and a high drug content were intended to exhibit a preferably prolonged release of highly water-soluble DS when prepared by the Wurster process–a spray coating method using a spouted bed assisted with a draft tube. The microcapsule was composed of a calcium carbonate core of 32–44 μm, a drug-layer of DS, hydroxypropyl cellulose and polyethyleneglycol 6000, an undercoat of Eudragit L30D and a release-sustaining coat of Eudragit RS30D. Eudragit L30D films were undercoated to decrease the solubility of DS within the environment of the microcapsules and thereby to prolong the drug release. This made it possible to decrease the amount of Eudragit RS30D membrane required to prolong the drug release, leading to decrease in the particle size of products and achievement of high drug content. As a result, prolonged release microcapsules with a mass median diameter of 92 μm and a drug content of 29% could be obtained.     

Novel time and site specific “tablets in capsule” system for nocturnal asthma treatment

The objective of present work was to develop a “tablets in capsule” system for facilitating both immediate and pulsatile drug deliveries of theophylline to mimic the circadian rhythm of nocturnal asthma. The system comprised of capsule filled with two tablets, first pulse and second pulse tablet prepared by wet granulation method. First pulse tablet was not coated and was responsible for providing loading dose whereas; second pulse tablet was coated with Eudragit L100 and Eudragit S100 to release drug in colon after specific lag time. Two independent variables, amount of polymers and coating thickness, were optimized by 3² full factorial design. The optimum formulation consisted of Eudragit L100: Eudragit S100 in 1:1.5 ratio and coating thickness of 20 % (w/w). In vitro drug release of “tablets in capsule” system in three different media (pH 1.2, pH 6.8, and pH 7.4) revealed immediate and pulsatile release patterns.     

Enteric coated HPMC capsules designed to achieve intestinal targeting.

The enteric coating of HPMC capsules containing paracetamol was investigated. Two enteric polymers, Eudragit L 30 D-55 and Eudragit FS 30 D were studied, which are designed to achieve enteric properties and colonic release, respectively. The capsules were coated in an Accela Cota 10, and, as shown by optical microscopy, resulted in capsules with a uniform coating. Scanning electron microscopy of the surface of the capsules illustrate that, in contrast to gelatin, HPMC has a rough surface, which provides for good adhesion to the coating. Dissolution studies demonstrated that capsules coated with Eudragit L 30 D-55 were gastro resistant for 2 h at pH 1.2 and capsules coated with Eudragit FS 30 D were resistant for a further 1 h at pH 6.8. The product visualisation technique of gamma scintigraphy was used to establish the in vivo disintegration properties of capsules coated with 8 mg cm(-2) Eudragit L 30 D-55 and 6 mg cm(-2) Eudragit FS 30 D. For HPMC units coated with Eudragit L 30 D-55, complete disintegration occurred predominately in the small bowel in an average time of 2.4 h post dose. For HPMC capsules coated with Eudragit FS 30 D, complete disintegration did not occur until the distal small intestine and proximal colon in an average time of 6.9 h post dose.     

Preparation and evaluation of slow-release pan-coated indomethacin granules

Abstract

Granules containing indomethacin crystals are coated with Eudragit solutions of different RL/RS ratios using a pan coating technique. The process is reproducible with regard to drug content, inexpensive and the formed granules were directly compressed into tablets. In vitro release of indomethacin from coated granules, tablets and capsules was studied as a function of different ratios of Eudragit RL/RS in the coating solution. The release of the drug was significantly reduced by the coating process in comparison with a formulation made from uncoated granules, prepared using 10 per cent gelatin solution as a binder. Release data were found to follow a diffusion-controlled model.     

Study of shellac glycerol esters as microencapsulating materials

Shellac esters were prepared by heating shellac with glycerol and intermediate reaction products were withdrawn. Salicyclic acid granules were encapsulated using a 20 per cent w/v alcoholic solution of shellac and shellac esters. The coated microcapsules were evaluated for moisture absorption, flow properties, and dissolution studies. The drug release from coated granules was seen to depend upon the acid value of the esters. Results indicate that shellac esters could be better encapsulating material than shellac in sustained release formulation.